Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50

Affiliations

• ¹ Pulmonary Department-Oncology Unit, "Theageneio" Cancer Hospital, Thessaloniki, Greece.
• ² Oncology Department, University of Thessaly, Larissa, Greece.
• ³ Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
• ⁴ Laboratory of Proteomics and Protein Sciences, Veterans Affair Health System, Baltimore, MD, USA.
• ⁵ Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200000, China.